ReviewClinical rheumatology2015
Abatacept as a successful therapy for myositis—a case-based review.
Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Abatacept for the treatment of myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Successful Treatment of Anti-Jo-1 Positive Inflammatory Myopathy With Tofacitinib.Case reports in rheumatology · 2026Article
- Successful treatment of rheumatoid arthritis complicated by anti-Jo-1 antibody-positive myopathy with abatacept: A case report.Fukushima journal of medical science · 2025Article
- Cytotoxic T-Lymphocyte-Associated Protein 4 Fused to a Modified Fragment of IgG1 Reduces Muscle Fiber Damage in a Model of Duchenne Muscular Dystrophy by Attenuating Proinflammatory Gene Expression in Myeloid Lineage Cells.The American journal of pathology · 2025Article
- Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.Journal of clinical medicine · 2025Review
- Treatment of Calcinosis in Juvenile Dermatomyositis.Current rheumatology reports · 2021Review
- A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy.Archives of rheumatology · 2020Article
- Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020Review
- Secondary Causes of Myositis.Current treatment options in neurology · 2020Review
- Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.Current treatment options in neurology · 2018Review
- Treatment in myositis.Nature reviews. Rheumatology · 2018Review
- Current Treatment for Myositis.Current treatment options in rheumatology · 2018Review
- Treatment of Juvenile Dermatomyositis: An Update.Paediatric drugs · 2017Review
- Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.Pediatric rheumatology online journal · 2017Article
- Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Clinical reviews in allergy & immunology · 2017Review
- Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.Clinical reviews in allergy & immunology · 2017Review
- Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Idiopathic inflammatory myopathies-a review.Clinical rheumatology · 2015Review
- Long-term efficacy of alemtuzumab in polymyositis.Rheumatology (Oxford, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Only limited evidence exists on the therapeutic potential of biologic agents in the treatment of myositis. We present a brief review of the literature on off-label experiences of biologic agents in myositis, with a special interest in abatacept. Rituximab has been indicated to be beneficial and well tolerated in one large randomized controlled trial and many smaller studies. Initial data on tumour necrosis factor (TNF) inhibitors are conflicting. There are only a few case reports and mechanistic studies on the treatment of myositis with other biologics, including alemtuzumab, anakinra, tocilizumab and abatacept. We report a patient with severe myositis overlap syndrome, manifesting also as rheumatoid arthritis, peripheral vasculitis and interstitial lung disease. Her myositis was refractory to many conventional and biologic therapies but was well controlled with abatacept. This suggests that abatacept might be a beneficial option for the treatment of refractory myositis and that clinical trials are needed to further investigate its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.